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OBJECTIVES The purpose of this study was to evaluate whether structural left ventricular (LV) abnormal-
ities can be observed in hypertrophic cardiomyopathy (HCM) mutation carriers who have not
yet developed echocardiographic signs of hypertrophy by using cardiac magnetic resonance
imaging (CMR).
BACKGROUND Hypertrophic cardiomyopathy is caused by mutations of genes encoding for sarcomeric
proteins. Myocyte disarray and interstitial fibrosis precede the development of regional
hypertrophy in HCM mutation carriers (carriers). No macroscopic LV structural abnormal-
ities have been observed in carriers without LV hypertrophy.
METHODS A CMR, echocardiogram, and electrocardiogram (ECG) were performed in 16 carriers.
Delayed contrast enhancement imaging was used with CMR to detect fibrosis. In 16 age- and
gender-matched control subjects, CMR and ECG were performed and an echocardiogram was
made when structural abnormalities were detected with CMR. All carriers had an LV wall
thickness 13 mm in the year before the study, measured by echocardiography.
RESULTS In 13 carriers (81%), crypts were discerned with CMR in the basal and mid inferoseptal LV
wall, not detected by routine echocardiography and not observed in healthy volunteers. In 4
of the crypt-positive carriers, both the echocardiogram and ECG were normal. Two HCM
carriers revealed regional hypertrophy of the inferoseptum not detected by echocardiography,
and in both carriers, focal fibrosis was present.
CONCLUSIONS In carriers who have not yet developed frank hypertrophy, crypts can be detected with CMR
in the inferoseptal LV wall, even when echocardiography and ECG are normal. The crypts
might represent one of the early pathological alterations of myocardium in carriers that
ultimately progress into manifest HCM. (J Am Coll Cardiol 2006;48:2518–23) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.036the American College of Cardiology Foundation
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sypertrophic cardiomyopathy (HCM) is a common dis-
ase, occurring in 1 in 500 in the general population, and
linically diagnosed by the presence of left ventricular (LV)
ypertrophy in the absence of a disease likely to cause this
ypertrophy (1).
Hereditary HCM is caused by mutations in genes, most
f which encode for sarcomeric proteins (2). Genetic
creening of families of index HCM patients enables the
dentification of HCM mutation carriers, whose echocar-
iographic dimensions of the LV might still be within the
ormal range. It is yet unclear how mutations in sarcomeric
roteins, which presumably affect all cardiac myocytes, give
ise to the usually regional myocardial hypertrophy.
Earlier studies in animals and human subjects have shown
hat myocyte disarray, fibrosis, relaxation abnormalities, and
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he Netherlands; †Department of Cardiology, Academic Medical Center, Amster-
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ccepted August 7, 2006.oncomitant left atrial enlargement precede the develop-
ent of frank hypertrophy in HCM mutation carriers (3,4).
e hypothesized that HCM mutation carriers exhibit local
tructural abnormalities before hypertrophy can be discerned.
Cardiac magnetic resonance imaging (CMR) has a high
patial resolution, is considered the gold standard for in vivo
etermination of mass and volumes of the LV, and enables
recise quantification of wall thickness and dimensions (5).
lso, CMR with delayed contrast enhancement (DCE)
maging can be used to detect foci of collagen deposition in
he myocardium of HCM patients (6).
Therefore, we used CMR to evaluate whether structural
V abnormalities can be observed in HCM mutation
arriers who have not yet developed echocardiographic signs
f hypertrophy.
ETHODS
atient selection. Hypertrophic cardiomyopathy mutation
arriers with an LV wall thickness 13 mm as measured by
-dimensional echocardiography in the year before the
tudy were selected. The HCM mutation carriers had either2373insG mutation in the gene encoding for cardiac
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December 19, 2006:2518–23 Crypts in HCM Mutation Carriersyosin-binding protein C (MYBPC3), which is found in at
east 25% of HCM patients in the Netherlands (7), or a
lu62Gln missense mutation in the gene encoding for
lpha-tropomyosin (TPM1) (8).
Other inclusion criteria were: sinus rhythm, age between
0 and 65 years, no signs and/or symptoms of coronary
rtery disease, and no history of a disease likely to cause
econdary LV hypertrophy. The structure and global func-
ion of the LV of HCM mutation carriers were compared
ith those of age- and gender-matched healthy volunteers.
Healthy volunteers, recruited from hospital employees,
ere included when having no history of cardiovascular
isease, no heart murmur or hypertension on physical
xamination, and a normal electrocardiogram (ECG). Fur-
hermore, first-degree relatives of healthy volunteers had to
e free of inheritable cardiomyopathy, (aborted) sudden
ardiac death, and/or unexplained syncope.
Exclusion criteria for all participants were: an implanted
acemaker, implantable cardioverter-defibrillator, cerebral
lips, known allergy to gadolinium-diethylenetriaminepenta-
cetic acid (DTPA), and/or claustrophobia.
In all HCM mutation carriers, a CMR, echocardiogram,
nd ECG were performed. A CMR and ECG were also
erformed in healthy volunteers. An echocardiogram was
nly performed in healthy volunteers when any abnormali-
ies were revealed by CMR.
The study was approved by our institutional ethics
ommittee. All participants gave written informed consent.
Table 1. Baseline Characteristics and Dimensi
Resonance Imaging
HCM Mutation C
(n  16)
Mean age (yrs) 40.7  12.
Male/female 6/10
Systolic BP (mm Hg) 114.8  12.
Diastolic BP (mm Hg) 65  9.1
LV EDV (ml/m2) 92.0  11.
LV ESV (ml/m2) 34.3  4.9
LV EF 62.7  3.7
LV mass (ml/m2) 56.2  11.
SWT (mm) 9  2.8
PWT (mm) 7.3  1.6
LA dimension (mm) 28.3  6.1
BP blood pressure; EDV end-diastolic volume; EF eje
Abbreviations and Acronyms
CMR  cardiac magnetic resonance imaging
DCE  delayed contrast enhancement
DTPA  diethylenetriaminepenta-acetic acid
ECG  electrocardiogram
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
MYBPC3  cardiac myosin-binding protein C
TPM1  alpha tropomyosincardiomyopathy; LA  left atrial; LV  left ventricular; PWT
maximal septal wall thickness.MR image acquisition. The CMR studies were per-
ormed on a 1.5-T whole body scanner (Magnetom Sonata,
iemens, Erlangen, Germany), with a 6-channel phased-
rray body coil. After survey scans, long-axis 4-, 3-, and
-chamber cines were acquired with a retro-triggered,
alanced steady-state free precession gradient-echo (true-
ISP) sequence.
Scan parameters were: 5-mm slice thickness with
-mm gap between short-axis slices, temporal resolution
50 ms, repetition time 3.2 ms, echo time 1.54 ms, flip
ngle 70°, and typical image resolution 1.3  1.6 mm. A
tack of 10 to 12 short-axis slices was used to cover the
V, as described previously (9). Acquiring additional cine
mages was left to the discretion of the attending cardi-
logist, a CMR specialist.
The DCE images were obtained 10 min after injection of
.2 mmol/kg gadolinium-DTPA. An inversion recovery
urbo Fast Low Angle Shot (FLASH) sequence was used to
btain images with 6-mm slice thickness planned at the
ame position as the long- and short-axis cines in end-
iastole. All images were obtained during breath holding in
ild expiration. The LV volumes and mass were obtained as
escribed previously (9). The LV volumes and mass were
ndexed to body surface area. End-systolic left atrial dimen-
ions were measured on 3-chamber view as the distance
etween the aortic root and posterior wall of the left atrium.
he presence of fibrosis and the structure of the LV were
valuated by a cardiologist experienced in CMR (A.C.vR.)
nd blinded to the genotype.
chocardiography. Two-dimensional and Doppler echo-
ardiography were performed on a Vivid-7 (General Elec-
ric Vingmed Ultrasound, Horten, Norway). Left ventricu-
ar structure and function were evaluated on parasternal and
pical views. Acquiring additional images was left to the
iscretion of the echocardiographer. Left ventricular struc-
ure and function were evaluated by a cardiologist (O.K.)
xperienced in echocardiography and blinded to the
enotype.
easured by Cardiac Magnetic
rs Healthy Volunteers
(n  16) p Value
40.1  11.3 NS
6/10 NS
122.7  12.7 NS
70.3  7.0 NS
92.5  11.0 NS
36.3  5.7 NS
60.8  3.2 NS
52.3  10.0 NS
7.5  1.2 NS
7.0  1.4 NS
29.8  5.2 NS
fraction; ESV end-systolic volume; HCM hypertrophicons M
arrie
7
7
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0
ction
 maximal left ventricular lateral wall thickness; SWT 
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Crypts in HCM Mutation Carriers December 19, 2006:2518–23CG. Standard 12-lead ECG was performed. Conduction
ntervals were measured, and LV hypertrophy was evaluated
ith the Romhilt-Estes criteria (10). The ST-segments
ere defined as normal or abnormal and, in addition, an
-wave in V13 mm was considered abnormal. The ECGs
ere analyzed by 2 observers blinded for the genotype (T.G.
nd A.A.M.W.).
enetic screening. Genomic deoxyribonucleic acid was
solated from blood samples. Sequencing protocols are given
n Alders et al. (7) and Jongbloed et al. (8).
tatistical analysis. An independent Student t test was
sed to compare groups. A p value of 0.05 was considered
ignificant.
ESULTS
he group of HCM mutation carriers comprised 5 TPM1
utation carriers (3 men) and 11 MYBPC3 mutation
arriers (3 men) from 7 different families. No HCM
utation carriers were excluded. Sixteen age- and gender-
atched healthy volunteers were included (6 men).
imensions and global LV function. Baseline character-
stics and global LV and left atrial dimensions measured
ith CMR did not differ between HCM mutation carriers
nd healthy volunteers (Table 1).
The CMR showed inferoseptal basal hypertrophy that
as not detected previously by echocardiography in 2
arriers with a septal wall thickness of 17 and 13 mm,
espectively (Table 2). In all other HCM mutation carriers,
aximal septal wall thickness, maximal lateral wall thick-
ess, LV mass, and left atrial dimensions were within
ormal limits. In the HCM mutation carrier with regional
ypertrophy, LV mass exceeded normal limits of 64.7 9.3
/m2 (11).
tructure. In the majority of HCM mutation carriers (13
f 16; 81%), CMR revealed an abnormal structure of the
yocardium consisting of profound crypts in the basal and
id segment of the inferoseptal LV myocardium, at the
unction of the right and left ventricle (Fig. 1). The crypts
ere only visible at end-diastole (Video [see Appendix]).
n LV short-axis images, they appeared as triangular,
lood-containing bright spots (Fig. 1). Importantly, the
yocardial segments surrounding the crypts were consid-
red normokinetic, both on CMR and echocardiography.
est visualization was obtained on subsequently acquired
edicated long-axis slices, slightly modified from the
-chamber view, cutting through the inferior septum (Fig. 1).
In HCM mutation carriers with an LV septal wall
hickness 9 mm, the crypts could be visualized within the
nferoseptal LV wall up to the subepicardium (Fig. 1). In
hose HCM mutation carriers with an LV wall thickness
anging from 9 to 12 mm, the crypts could be visualized
nly throughout 70% of the inferoseptal LV wall. The 1
CM mutation carrier who had 17-mm LV wall thickness
evealed only 1 remnant crypt at the border of the regionally
ypertrophied segment. The 3 HCM mutation carriers who Ta
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December 19, 2006:2518–23 Crypts in HCM Mutation Carriersad no discernable crypts were all women and were
YBPC3 mutation carriers.
All healthy volunteers had normal LV myocardium with-
ut the structural abnormalities described in the preceding
ext.
Focal fibrosis within the septal wall was present in the 2
CM mutation carriers with regional hypertrophy. Fibrosis
as absent in all other HCM mutation carriers and healthy
olunteers. However, the crypts did mimic focal fibrosis by
artial volume effects on short-axis DCE images (Fig. 2).
CG. None of the HCM mutation carriers met the criteria
or LV hypertrophy (Table 2). In 2 (15%) crypt-positive
arriers, ST-segments were abnormal. An R-wave in V13
m was found in 9 of the crypt-positive carriers. In total,
3% of the crypt-positive carriers had an abnormal ECG.
f the 3 HCM mutation carriers who had no detected
rypts, 2 had a normal ECG and 1 had an abnormal ECG.
ISCUSSION
ypertrophic cardiomyopathy is characterized by a large
nterfamilial and intrafamilial variety of clinical presenta-
ions, ranging from sudden cardiac death at young age to
ild symptoms of heart failure at advanced age, even if a
ingle mutation is involved. Therefore, research is often
ocused on early identification of HCM mutation carriers
ho are at increased risk for developing heart failure or
otentially life-threatening arrhythmias (12–14).
This study is the first to report that structural abnormal-
ties consisting of crypts that can be detected in the LV
yocardium of many asymptomatic HCM mutation carri-
rs, in whom no hypertrophy has developed yet, no fibrosis
igure 1. Structural abnormalities in hypertrophic cardiomyopathy (HCM
rrowhead indicates triangular shaped, blood-containing spot in inferose
odified 2-chamber view through inferoseptum of healthy volunteer; no cr
f HCM mutation carriers with left ventricular (LV) wall thickness 9
ubepicardial layer. (F) Modified 2-chamber view through inferoseptum of
he crypts can be visualized only up to 70% of the myocardium, as indicas present, and no ECG abnormalities occur. The crypts were best visualized in end-diastole with CMR, not with
outine echocardiography. When LV wall thickness was9
m, crypt penetration could be visualized up to the sub-
picardial layer of the myocardium. The depth of crypt
enetration decreased with the increase of LV wall thick-
ess. In 1 HCM mutation carrier who had developed overt
egional hypertrophy, only a single crypt was visible at the
order of the hypertrophied area, suggesting that this might
e a remnant of crypts that have been compressed by
urrounding hypertrophied myocardium. This might also
xplain why crypts have never been described previously in
athology studies. So far, pathology studies have described
n detail the macroscopy, microscopy, and histology of the
yocardial structure in patients with overt HCM but not in
arriers without hypertrophy (15,16). Furthermore, post-
ortem analyzed hearts are always to some extent in a
ontracted state, which makes detection of the crypts more
ifficult. In vivo study by CMR, however, allows detailed
nalysis of the myocardium in the non-contracted, end-
iastolic state. Thus, the recent availability of genetic
dentification of pre-symptomatic HCM mutation carriers,
n combination with the tomographic precision provided by
MR, resulted in the discovery of macroscopic abnormal-
ties in this patient group.
Although the HCM mutation carriers in our study were
symptomatic, the crypts might induce regional function
bnormalities and conduction disorders. If one assumes that
rypts are the result of regional ischemia due to coronary
icrovascular dysfunction and/or myocyte disarray, both
allmarks of HCM (1), then the presence of crypts might
ead to loss of contractility within the area of myocardium
utation carriers. (A) Short-axis view of HCM mutation carrier. White
. Gray cutline represents the image plane of images B through F. (B)
an be observed. (C to E) Modified 2-chamber view through inferoseptum
white arrowheads indicate crypts penetrating the myocardium up to the
mutation carrier with LV wall thickness of 11 mm. The penetration of
white arrowheads.) m
ptum
ypts c
mm;here the crypts are located (17). This assumption is in
a
N
t
c
t
y
t
a
t
o
d
s
m
a
D
t
h
i
M
c
p
l
D
f
l
d
r
o
m
r
H
m
e
t
s
w
s
t
h
d
p
v
s
F
m
2
m
S . Blac
D
2522 Germans et al. JACC Vol. 48, No. 12, 2006
Crypts in HCM Mutation Carriers December 19, 2006:2518–23greement with the results of a clinical study performed by
agueh et al. (4), who evaluated myocardial function with
issue Doppler imaging in asymptomatic HCM mutation
arriers. They found that early diastolic myocardial veloci-
ies were reduced in HCM mutation carriers who had not
et developed hypertrophy. Thus, one might hypothesize
hat crypts lead to a loss of contractility, which in turn serves
s a trigger to develop hypertrophy (18). However, we found
he myocardium surrounding the crypts to be normokinetic
n both cine imaging and routine echocardiography, which
oes not support this hypothesis. Whether more subtle
ystolic or diastolic abnormalities of the myocardial seg-
ents surrounding the crypts can be detected with more
dvanced functional imaging techniques, such as tissue
oppler imaging by echocardiography or myocardial tissue
agging by CMR, needs to be further evaluated.
In this study, regional fibrosis was observed within the
ypertrophied region of 2 HCM mutation carriers. This is
n accordance with the results of a study performed by
oon et al. (19), who found that fibrosis was not present in
arriers of troponin I mutations who had no LV hypertro-
hy or electrocardiographic abnormalities. Nevertheless, the
igure 2. Delayed contrast enhancement images of hypertrophic cardiom
utation carrier with regional hypertrophy. White arrowhead indicates fo
-chamber view of HCM mutation carrier without regional hypertrophy;
utation carrier with regional hypertrophy. White arrowhead indicates
hort-axis view of HCM mutation carrier without regional hypertrophy
ashed line indicates cutline of image B.ocation of the crypts is similar to the typical location of the mCE in HCM patients. This suggests that crypts as well as
ormation of focal replacement fibrosis, which is the histo-
ogical counterpart of DCE (6,20), might both reflect 2
ifferent stages of the same disease process that ultimately
esults in manifest HCM. However, investigating the role
f the crypts on regional myocardial function and develop-
ent of regional hypertrophy with subsequent focal fibrosis
equires a long-term follow-up study with a large variety of
CM mutation carriers. In addition, acquiring histology of
yocardium surrounding the crypts might enable research-
rs to learn more about the histopathlogical background of
he crypts.
We found that CMR was more sensitive in detecting
tructural abnormalities than routine echocardiography;
hether the use of contrast agents might increase the
ensitivity of echocardiography in detection of crypts has yet
o be evaluated. Furthermore, CMR identified regional
ypertrophy in 2 HCM mutation carriers, which was not
etected by echocardiography. This is consistent with a
revious report (21). Importantly, the crypts were only
isualized within the basal and mid segments of the infero-
eptal LV wall. Therefore, the awareness for the need of
thy (HCM) mutation carriers. (A) Modified 2-chamber view of HCM
brosis; dashed line indicates the cutline of image plane C. (B) Modified
ed line indicates the cutline of image D. (C) Short-axis view of HCM
fibrosis in inferoseptum; dashed line indicates cutline of image A. (D)
k arrowhead indicates partial volume effect of blood-containing crypts.yopa
cal fi
dash
focalaking dedicated modified imaging planes through the
i
t
t
d
t
S
t
H
r
p
h
t
e
t
b
c
C
i
c
m
l
l
R
D
B
t
R
1
1
1
1
1
1
1
1
1
1
2
2
A
T
2523JACC Vol. 48, No. 12, 2006 Germans et al.
December 19, 2006:2518–23 Crypts in HCM Mutation Carriersnferoseptum to detect the crypts might increase the sensi-
ivity to identify HCM mutation carriers.
Thus, CMR might indeed serve as a valuable additional
ool to identify HCM mutation carriers in an early stage of
isease, thereby allowing timely initiation of risk stratifica-
ion and therapy.
tudy limitations. We studied 2 groups of common mu-
ations in the Netherlands, and sample size was limited.
owever, whether the crypts can be found in all HCM-
elated mutation carriers who have not developed hypertro-
hy and the role of the crypts in the development of HCM
ave yet to be determined. We used a gap of 5 mm between
he LV short-axis slices. Therefore, we did not cover the
ntire LV myocardium to screen for structural abnormali-
ies. Acquiring a stack of LV short-axis slices with no gap
etween the slices might increase the sensitivity to detect
rypts.
onclusions. The integrity of the inferoseptal LV wall is
nterrupted by crypts in many HCM mutation carriers and
an be detected by CMR. The crypts are visualized in HCM
utation carriers, whose LV wall thickness is within normal
imits and whose routine echocardiography and ECG show
ittle or no abnormalities.
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PPENDIX
o view the video referenced in the text, please see the
nline version of this article.
